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Abstract 
Three-dimensionally organized lipid cubic self-assemblies and derived oil-in-water emulsions 
called ‘cubosomes’ are attractive for various biotechnological applications due to their ability 
to be loaded with functional molecules and associated sustained release properties. Here we 
employed both lipid-based systems for the delivery of a model drug – aspirin under comparable 
conditions. Studies were performed by varying drug to lipid ratio and the type of release 
medium, water and phosphate buffer saline (PBS). Release rates were determined using UV-
Vis spectroscopy while small angle X-ray scattering confirmed the type of self-assembled 
nanostructures in lipid systems. The release from bulk lipid cubic phase was sustained as 
compared to the dispersed cubosomes while the release in PBS was efficient than in water. 
Highly tortuous architecture, length of the diffusion pathway, type of nanostructure and 
physicochemical interaction with the release media evidently contribute to these observations. 
This work is particularly important, as it is the first report where both of the nanostructured 
lipid systems were studied together under similar conditions. The work provides important 
insights in understanding, and therefore controlling the release behaviour of lipid-based drug 
nanocarriers. 
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Introduction 
Lipids, generally composed of hydrophilic and hydrophobic molecular components (Figure 
1a), tend to self-assemble in presence of aqueous media. Self-assemblies can be as simple as 
spherical micelles and planar bilayers or they can be quite elegant like hexagonal and cubic 
phases1-2. Based on the spatial organisation, lipid cubic phases are divided into two types3, 
bicontinuous and micellar3. Most common bicontinuous cubic phases (Figure 1b), defined by 
crystallographic space groups Ia3d (no. 230), Pn3m (no. 224) and Im3m (no. 229), are formed 
by draping a continuous lipid bilayer on Gyroid (G), diamond (D) and primitive (P) type 
periodic minimal surfaces, respectively3-4. The term ‘bicontinuous’ can be interpreted in two 
possible ways, 1) continuity of two networks- first made of a continuous bilayer and second 
made of continuous waterways, and 2) presence of two continuous aqueous channels separated 
by a single lipid bilayer5. Micellar cubic phases, on the other hand, are formed by an 
arrangement of discrete micelles in a cubic lattice3. Typical example of a micellar cubic phase 
is Fd3m phase6.  
  
Figure 1: Schematic diagram depicting cubic phases, cubosomes and release set-up (not 
on scale): a) Chemical structures of a lipid molecule, a surfactant stabilizer and a drug. Blue 
and yellow colour shades code for hydrophilic and hydrophobic parts/regions, respectively. b) 
Page 3 of 21 
 
Bicontinuous cubic phases of Im3m, Pn3m and Ia3d types with corresponding 6, 4 and 3 
aqueous channels as represented by arrows. c) Highly viscous cubic phase (Pn3m in the current 
study) is shown at the bottom of 20 ml glass bottle. d) Graphics of cubosome on the left displays 
Im3m phase as an internal self-assembly while the surfactant molecules stabilize the interface; 
dispersion of such cubosomes is shown on the right. e) Cubosome dispersion is essentially a 
form of an oil-in-water emulsion, which exhibits fluid and milky consistency. f) A beaker 
containing water/PBS with a dialysis membrane holding drug-loaded cubosomes. It represents 
a typical drug release set-up employed in the current work.   
   
Bicontinuous cubic phases are equipped with a range of structural features responsible for their 
applicability; for instance, a) enormous surface area (400 m2/g)7 b) large surface to volume 
ratio c) physicochemical ability to load hydrophilic molecules in aqueous region, hydrophobic 
molecules in lipid chain region and amphiphilic molecules in bilayers8 d) continuous 
trajectories for uninterrupted diffusion of loaded molecules5 e) viscoelastic nature for the 
stability and structural integrity of loaded molecules9 f) highly organized porous network for 
nanoscale templating10 and g) resemblance with biomembrane structures11. Thermodynamic 
equilibrium12 and robustness under given conditions, and high level of tunability are further 
aspects. However, the preparation and the handling of cubic phases are not simple protocols 
due to inherent high viscosity (complex viscosity in the range of 104-105 pa.s)13(Figure 1c). 
Two possible ways to overcome these hurdles are, to utilize mechanical tools to handle cubic 
phases14-16 or to disperse them into a fluid form17-18(Figure 1d, e). The latter means provides 
additional benefits, for instance, improved surface to volume ratio19, availability of enormous 
aqueous reservoir (up to 95-96% of the volume)20-21, rather simple preparation protocols, low 
overall viscosity and rather regular domains (monodispersed or low poly-dispersity particles)19. 
Moreover, dispersed lipid particles have great potential for engaging in targeted and tracked 
delivery applications21-29. Upon dispersion, the cubic phase is retained within the lipid particles 
hence the term ‘cubosomes’ (Figure 1e) is used to describe them17. As compared to vesicles or 
liposomes, the cubosomes exhibit higher bilayer area to particle volume ratios19, in other 
words, the cubosomes possess much larger hydrophobic volume fractions (corresponding 
values of 0.59 nm3 as compared to 0.18 nm3 for 100 nm sized particles)21. This feature is very 
important for enhanced drug carrier capacity, especially of poorly water-soluble drugs19. In 
addition, the cubosomes are much more robust and stable owing to rather high viscous 
resistance to rupture19.  
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There are several reports demonstrating the delivery applications of bulk lipid cubic phase30-39 
as well as dispersed nanoparticles like cubosomes 7, 19, 40-46 but there is hardly any record where 
both of the lipid systems are studied together under comparable conditions. In this work, we 
examined the release properties of bulk (non-dispersed) lipid cubic phase and it’s dispersed 
form i.e. cubosomes for a model drug called aspirin (Figure 1a). Aspirin is an important drug 
exhibiting analgesic, antipyretic and anti-inflammatory properties. Moreover, it was shown to 
increase the solubility of cholesterol plaques within the membrane47 and increase its fluidity. 
However, aspirin has some predominant side effects including the toxicity of the 
gastrointestinal (GI) tract and rapid conversion into less desired products48. Therefore, its 
encapsulation into optimal delivery system would be largely beneficial48. We monitored the 
release of aspirin from bulk lipid cubic phase and cubosomes, in water and PBS media (Figure 
1f), using UV-Vis spectroscopic technique.    
 
Materials and Methods 
Materials:  
A lipid, Dimodan U/J® (DU) was generously provided by Danisco, A/S (Brabrand, Denmark). 
It is a distilled glyceride comprising 96% monoglycerides (Figure 1a) and the rest are 
diglycerides and free fatty acids. Two major monoglyceride components in DU are linoleate 
(62%) and oleate (25%). Hence the hydrophobic part of DU mainly contains C18 chains (91%). 
The following chemicals/items were purchased from Sigma-Aldrich (Dorset, UK): triblock 
copolymer Pluronic® F127 (PEO99-PPO67-PEO99) (Figure 1a); used to stabilize lipid particles- 
cubosomes, aspirin (Chemical name Acetylsalicylic acid); it is a salicylate drug (Figure 1a) 
used mainly as analgesic and antipyretic agent, phosphate buffer saline (PBS) tablets, and 
dialysis membrane sacks (with an average flat width of 35 mm, MWCO 12,000 Da). All the 
chemicals were used as received without any further purification. DU was stored below 4°C 
whereas the other materials were kept at room temperature when not in use. Water used during 
the entire study was purified using Barnstead Nanopure, Thermoscientific (USA). 
Standard calibration curves of a drug in water and PBS 
50 mg of aspirin was dissolved separately in 10 ml distilled deionised water (now on referred 
as ‘water’) and 10 ml 0.01 M PBS buffer (one tablet dissolved in 200 ml of deionized water 
yields 0.01 M phosphate buffer with pH ~7.4, now on referred as ‘PBS’) in 100 ml volumetric 
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flasks. The mixtures were sonicated for 5 min (Sonics & Materials Vibra-Cell VCX750, 
Jencons, UK) to ensure the drug dissolution. Finally, the corresponding volumes were made 
up to the mark with water and PBS to make 0.5 mg/ml stock solutions. Standard solutions were 
prepared by appropriate dilutions of above stock solutions. The absorption spectra of aspirin 
solutions were determined in the ultra-violet visible (UV) range of 200-800 nm with the 
characteristic λmax at 276 nm (UV-1600PC, VWR, UK). At least 10 dilutions, in the range of 
0.1 to 100 µg/ml concentrations, were utilized to establish standard calibration curves at the 
λmax (see supporting information Figure S1). All measurements were performed in triplicates 
at room temperature (~25 °C). 
Preparation and loading of a drug in the cubic phase (bulk lipid phase) 
The bulk lipid phase was prepared by melting 2 g lipid (DU) in a 20 ml glass vial followed by 
addition of equal amount of water (by weight) yielding a known Pn3m cubic phase49 (Figure 
1c). Drug-loaded bulk phase was prepared as follows: a mixture of appropriate drug 
concentration and 1 g molten DU was stirred (using magnetic stirrer bar) for 30 min at 50 °C 
followed by an addition of 1 g water. During the release experiments, further 9 g water was 
added to 1 g cubic phase in order to maintain comparable concentrations with cubosomes 
solution. Hydrated phase was physically mixed with the spatula and allowed to stand overnight 
at room temperature.  
Preparation and loading of a drug in cubosomes (dispersed lipid particles)   
The nanostructured lipid particle dispersions i.e. cubosome solutions, were prepared according 
to the published method albeit slightly different parameters and compositions50. 500 mg of 
molten lipid (DU) was added to the 20 ml glass vial and topped with 9.5 g F127 stabilizer 
solution (already prepared by dissolving 0.5% Pluronic F127 powder in 100 g water). The 
resulting (10 g) mixture was ultra-sonicated (Sonics & Materials Vibra-Cell VCX750, Jencons, 
UK) for 5 min with a continuous pulse using 35% of the maximum power. Sample (milky fluid 
emulsion, Figure 1e) became hot due to ultra-sonication and was left to cool down to room 
temperature before further usage.  Drug-loaded samples were prepared by stirring appropriate 
weight of a drug in above cubosome solution for about 20 min at 50 °C. 
Drug lipid mixtures and a release set-up 
10 g of drug-loaded bulk cubic phase mixture (containing 1 g lipid cubic phase and 9 g water) 
and 10 g dispersed cubosomes were loaded with a range of drug concentrations to obtain final 
samples of 2 %, 4 %, 6% and 10% wt/wt drug/lipid. Above samples were carefully transferred 
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into dialysis membrane sacs (which were prepared by heating in pure water for 10 min at 80 
°C). Both ends of membrane sacs were tightly tied to avoid sample leakage. Finally the 
membrane sacs were individually immersed into 200 ml of either water or PBS in 500 ml 
beakers. 3 ml solution from aforementioned release set-up (beaker) was collected after periodic 
timescales including t=0 min, and the UV-Vis spectroscopic data was measured at λmax of 276 
nm. After measurements, the solutions were poured back into the original reservoirs to maintain 
accumulative release conditions. Studied drug concentrations were well within the sink 
conditions51.      
Entrapment efficiency (%) and drug loading (%) in cubosomes and bulk cubic phase 
1 gm of  drug (2%) loaded dispersed cubosomes were added to 1.5 ml Eppendorf tube and 
centrifuged at 13,200 rpm for 10 min (Spectrafuge 24D from Jencons Pls). The fluid phase was 
transferred into an empty Eppendorf tube and centrifuged for further 10 min. Majority of the 
cubosome particles were removed by this method; however, the emulsion retained the opacity. 
The remaining lipid was separated by using Amicon Ultra-0.5 Centrifugal Filter Unit with 
Ultracel-3 membranes (NMWL 3 KDa, Millipore, USA) with 20 min centrifugation at 13,200 
rpm. The separated aqueous phase was diluted with water and the absorbance at 276 nm was 
measured using UV-Vis spectroscopic technique. The entrapment efficiency (EE) and drug 
loading (DL) was determined using following formulae52. 
𝐸𝐸𝐸𝐸 = �1 − 𝐶𝐶𝑈𝑈
𝐶𝐶𝑇𝑇
� × 100 …………………………………………………… (1) 
𝐷𝐷𝐷𝐷 = �𝐶𝐶𝑇𝑇−𝐶𝐶𝑈𝑈
𝐶𝐶𝐿𝐿
� × 100 ……………………………………………..……… (2) 
where, 𝐶𝐶𝑈𝑈 is the concentration of non-entrapped drug (free unloaded drug), 𝐶𝐶𝑇𝑇 is the concentration of 
drug added to the cubosome dispersion and 𝐶𝐶𝐿𝐿 is the total lipid content. The EE and DL for other 
cubosome dispersions (with 4, 6, and 10% drug) were determined in the same manner as 
descried above. The excess water (aqueous phase) from drug-loaded bulk cubic phase system 
was separated simply by decanting into empty cuvettes followed by recording their absorbance 
at 276 nm. The EE and DL values for 2, 4, 6 and 10% drug-loaded bulk cubic phase samples 
were determined subsequently using above formulae (eqs. 1 and 2). 
Particle size analysis of cubosome dispersions 
The mean particle size and size distribution of cubosome dispersions were measured using 
Zetasizer Nano ZS instrument (Malvern Instruments, UK) operated at 25 °C.   
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Detecting the type of lipid nanostructure using Small angle X-ray scattering 
Small angle X-ray scattering (SAXS) was used to detect the type of lipid nanostructure of bulk 
and dispersed lipid systems (Figure 2). The SAXSpace instrument (Anton Paar, Graz, Austria) 
at University of Leeds was employed for this purpose. The details of the instrument and 
measurement are published earlier53. The instrument is based on Cu-anode operating at 40 kV 
and 50 mA. Samples were measured using capillary sample holder controlled at 25±0.1°C. 
Typical exposure times of 300 sec were sufficient to obtain patterns with well-resolved peaks 
(Figure 2).   
 
Results and Discussion 
Nanostructural characterization and drug loading capacity of bulk cubic phase and 
cubosomes 
The type of nanostructural self-assembly was determined using SAXS for drug-loaded and native lipid 
systems. The bulk DU formed Pn3m type bicontinuous cubic phase in excess water49, which was 
retained upon addition of 10% drug (Figure 2a). In case of dispersed lipid systems, the addition of 
stabilizer molecules usually cause phase transition into Im3m type bicontinuous cubic phase20, 54-55 
(Figure 2b).   
 
Figure 2: Detection of the type of lipid self-assembly using SAXS: a) Pn3m cubic phase was 
observed in pure and drug-loaded (10% drug) bulk lipid system. b) Im3m cubic phase was 
observed in pure and drug-loaded (10% drug) dispersed cubosome system. Characteristic 
Bragg’s diffractions for Pn3m (√2, √3, √4, √6) cubic phase and Im3m (√2, √4, √6) cubic phase 
are shown near corresponding peaks. Aqueous channels are indicated by arrows.   
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The ultrasonic dispersion process created discrete lipid particles with an internal nanostructure 
of cubic phase. These cubosomes exhibited sub-micron size as verified by the particle size 
analysis (for plot see supporting information Figure S2). The particle size values for native and 
drug-loaded cubosomes are listed in Table 1.  
Drug in Dispersion 
(Wt% per Wt of lipid) 
Average Particle Size 
nm 
PDI 
(Poly dispersity index) 
0 194±4 0.210 
2 184±3 0.192 
4 183±3 0.207 
6 182±2 0.205 
10 184±1 0.184 
Table 1. Particle size and polydispersity indices of native and drug-loaded cubosomes 
measured by dynamic light scattering technique Zetasizer Nano ZS.  
An entrapment efficiency of bulk lipid cubic phase in excess water and cubosomes dispersions 
was calculated using eq. 1 as shown in Table 2. Similarly, drug loading in lipid cubic phase 
and cubosome particles was calculated using eq 2 and shown in Table 2. The EE and DL values 
for bulk cubic phase were higher as compared cubosome system. The low DL values 
demonstrate that the drug is preferably located in the aqueous phase rather than lipid structures. 
Upon encapsulation in lipid systems and subsequent dehydration, the structural features of a 
drug (aspirin) are generally protected as reported in our previous work56. However, lipid 
systems employed in the current study were always in excess water condition permitting the 
drug encapsulation in both, lipid and aqueous regions (Table 2).   
Drug  
loading 
EE bulk cubic phase 
in excess water 
EE cubosome 
dispersion 
DL  
cubic phase 
DL 
cubosomes 
Wt %/Wt of 
lipid 
% % % % 
2 84.1 61.9 0.39 0.25 
4 98.7 67.6 0.91 0.54 
6 98.5 71.3 1.36 0.86 
10 96.6 71.6 2.22 1.43 
Table 2. Entrapment efficiency (EE) and Drug Loading (DL) in bulk lipid phase and dispersed 
cubosomes.  
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Drug release from bulk cubic phase 
Referring to the standard calibration curves obtained by dissolving various concentrations of a 
drug in water and PBS (supporting information Figure S1), the measured absorbance values at 
λmax of 276 nm were translated into percentage (%) release values. These values were then 
plotted against time recorded in hours for release in water (Figure 3) and in PBS (Figure 4) for 
bulk cubic phase.     
 
Figure 3: Drug release from bulk cubic phase in water: a) Percent (%) drug release 
calculated from corresponding absorbance values (at λmax of 276 nm) are shown against time 
in hours for 2, 4, 6 and 10% drug. b) Curves in a) were fitted with Korsmeyer-Peppas equation 
to obtain the release rates (%/hr), which are plotted against the drug to lipid ratio values.  
 
The curves in Figures 3 and 4 essentially followed typical drug release kinetics. Their 
logarithmic plots fitted well (with correlation coefficients- R2 values >0.96) with characteristic 
Korsmeyer-Peppas equation (eq. 3)57-58; for representative fits, see supporting information 
Figure S3.  
𝑀𝑀𝑡𝑡
𝑀𝑀∞
� = 𝐾𝐾𝑡𝑡𝑛𝑛…………………………………………………………………… (3) 
where, Mt is the amount of drug released at time ‘t’, M∞ is the total amount of drug in the 
formulation, K is a kinetic constant, n is the exponent – characteristic of the release mechanism 
and t is the release time in hours. 
The drug release in water medium became insignificant after about 30 hrs (Figure 3a) but it 
was gradual and well-detectable up to about studied 96 hrs in case of PBS release medium 
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(Figure 4a). Slopes of the fit lines, i.e. release rates in %/hr follows a linear trend except for 
10% drug sample (Figures 3b and 4b). The corresponding slopes of these lines were 
comparable: 0.05198 %Wt%hr-1 for release in water (Figure 3b) and 0.04701 %Wt%hr-1 for 
release in PBS medium (Figure 4b). Both release rates are dependent on the drug concentration 
and follow first-order kinetics.    
 
Figure 4: Drug release from bulk cubic phase in PBS: a) Percent (%) drug release calculated 
from corresponding absorbance values (at λmax of 276 nm) are shown against time in hours for 
2, 4, 6 and 10% drug. b) Curves in a) were fitted with Korsmeyer-Peppas equation to obtain 
the release rates (%/hr), which are plotted against the drug to lipid ratio values. 
 
Drug Release from dispersed cubosomes  
The release trends from cubosomes (Figure 5) virtually followed similar release patterns as 
from bulk cubic phase (Figures 3 and 4). The release in water saturated after about 30 hrs 
whereas it continued gradually in case of PBS.  
Page 11 of 21 
 
 
Figure 5: Drug release from dispersed cubosomes in a) water and b) PBS: Percent (%) 
drug release calculated from corresponding absorbance values (at λmax of 276 nm) is plotted 
against time in hours for 2, 4, 6 and 10% drug/lipid for release in water a) and in PBS b). 
 
However, the release from cubosomes in water (Figure 5a) appears to be less dependent on the 
drug concentration as evident from the closely positioned release curves. Nevertheless, the 
release curves on log-log scale, both in water and in PBS, were fitted using Korsmeyer-Peppas 
equation (eq. 3)57 with typical R2 values >0.93.  
 
Sustained drug release from bulk cubic phase compared to cubosomes 
Comparing the release rates from cubic phases and cubosomes (Figure 6), it is clear that the 
release from cubosomes was faster than the release from bulk cubic phases. The release of 2% 
drug from bulk cubic phase was found to be three-folds (0.233 %/hr) sustained than the release 
from cubosomes (0.658 %/hr) when measured in water; whereas it was twice more sustained 
from bulk cubic phase (0.190 %/hr) than from cubosomes (0.402 %/hr) in PBS. The same trend 
was also observed for the release rate values of 4 % drug in water (0.283 %/hr for bulk cubic 
phase and 0.637 %/hr for cubosomes) and in PBS (0.282 %/hr for bulk cubic phase and 0.407 
%/hr for cubosomes). The releases for 6% and 10% drug from cubosomes were also faster than 
the releases from bulk cubic phases, both in water and PBS release media.  
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Figure 6: Comparison of drug release from bulk cubic phase and cubosomes: % release 
for 2% drug in a) water and b) PBS and 4% drug in c) water and d) PBS are shown with time 
in hrs.   
 
Fittingness of Korsmeyer-Peppas equation to almost all curves in both lipid systems helps to 
understand the underlying release mechanisms. Analysis of the exponent n (eq. 3) suggest that 
the release mechanism is a Fickian diffusion when n value is less than or equal to 0.45 (n≤0.45). 
The release from bulk cubic phase, both in water and in PBS followed this mechanism. 
Apparent Fickian diffusion is known to contribute in sustaining the release of small molecules 
from bulk cubic phases30-31, 35-39. This can be easily attributed to the highly tortuous porous 
morphology of cubic phases. In order to release from the bulk cubic phase, the drug molecule 
has to navigate through the lengthy aqueous network assimilated by long and continuous lipid 
bilayer architecture. On the contrary, the release from cubosomes is rapid and less sustained 
(Figure 6). This is due to smaller (< 200 nm, Table 1)53 particle size correlated to smaller length 
scales for the drug transport, and too high surface area accountable to the burst release 
kinetics59. The release from cubosomes in water displayed n value below 0.45 but for the 
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release in PBS the n value was greater than 0.45 (n=0.63) depicting anomalous or non-Fickian 
diffusion kinetics57-58.    
A few recent reports demonstrate that the release rates from lipid systems can be controlled by 
fine-tuning nanostructural type and dimensions of the self-assembled phases30-32, 60-62. For 
instance, if the nanostructure is hexagonal phase, the release can be more controlled in 
comparison to the open structured cubic nanostructures34, 63. Moreover, the release could be 
administered via stimuli responsive (pH, light or temperature induced) triggers63-65. We have 
recently demonstrated that it is possible to sustain the release from cubosomes by encapsulating 
them into hydrogel films56, 66. The release, in this case, is believed to occur in multiple steps 
involving hydration of the hydrogel film, swelling and subsequent erosion of the hydrogel, 
opening of the aqueous channels of cubosomes, burst release and finally the dissolution of the 
hydrogel matrix56.  
The nanoscale design and dimensions of the cubic self-assemblies further influence the release 
kinetics as follows. The lipid used in this work forms Pn3m type cubic phase in pure water49 
(Figure 2a). This phase exhibits four aqueous channels (meeting at tetrahedral angle) whereas 
the internal self-assembly of cubosomes is found to be Im3m phase (Figure 2b) consisting six 
aqueous channels (meeting at right angles). Moreover, the aqueous channels of Im3m phase 
are usually larger than Pn3m phase for the same lipid system, see Table 3. Largely hydrophilic 
block co-polymer stabilizers, similar to F127 used in this work, are known to alter the average 
molecular shapes of cubic phase forming lipids20, 54; most common result is the formation of 
Im3m phase in the internal cores of dispersed cubosomes55.    
Physical 
form of lipid 
system 
Concentration 
of drug Wt% 
per lipid Wt. 
Type of self-
assembled 
cubic phase 
No. of 
aqueous 
channels 
Lattice 
Parameter 
(a),   Å 
Diameter of 
aqueous 
channel (dw), Å 
Bulk cubic 
phase 
0 Pn3m 4 89.5 37.9 
Bulk cubic 
phase 
10 Pn3m 4 103.2 48.7 
Dispersed 
cubosomes 
0 Im3m 6 135.6 50.9 
Dispersed 
cubosomes 
10 Im3m 6 146.7 57.8 
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Table 3. Nanoscale dimensions of lipid cubic phases formed in bulk system and dispersed 
systems, before and after drug loading. Lattice parameters and diameters of aqueous channels 
were calculated according to the formulae listed in reference67. 
 
Encapsulation of a drug further elevates diameters of aqueous channels by about 22% in bulk 
cubic phase while 12% in cubosomes (Table 3). Thus, the number of aqueous channels and 
their sizes are greater in the cubic phase (Im3m) of cubosomes as compared to the bulk cubic 
phase (Pn3m), which theoretically contribute to rather rapid release from cubosomes.    
 
Efficient release in PBS than in water 
The drug release from all samples, in bulk cubic phases and cubosomes, in PBS was far more 
efficient (more than double in some cases) than the release in water (Figure 7, Table 4). PBS 
medium (pH ~7.4) is generally referred to be the physiological condition where drug release 
kinetics is usually different than in ambient and pure conditions.  
 
Figure 7: Drug release in PBS compared to water: a) Percent (%) drug release in water (solid 
squares) and in PBS (solid circles) for 2% drug/lipid is shown for a) bulk cubic phase and b) 
cubosome system. Note that the representative data plots for 2% drug/lipid samples are shown 
here; for remaining data plots (4%, 6% and 10% drug/lipid) see supporting information Figure 
S4.    
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Drug (Wt% / 
Wt of lipid) 
Bulk Cubic Phase 
in Water, % 
Bulk Cubic 
Phase in PBS, % 
Cubosomes in 
Water, % 
Cubosomes in 
PBS, % 
2 33.65 45.12 30.93 56.53 
4 24.62 41.11 29.47 44.39 
6 22.91 34.39 29.16 41.67 
10 20.09 31.05 18.23 38.96 
Table 4. The % release at 24 hrs from both lipid systems in water and in PBS. 
Main advantages of employing PBS for release studies include the retention of constant pH, 
prevention from denaturation and/or conformational changes, resembling the bodily conditions 
(isotonic) and nontoxicity to cells68. However, biological buffers, and also associated pH 
affects the membrane properties68-69.  It was envisaged that the buffer molecules interact with 
hydrophilic lipid head groups and intercalate within the head group region facilitating the 
reduction of membrane bending modulus and increase in number of membrane fluctuations69. 
The overall effect of these events is revealed in the form of swelling68 and/or softening of lipid 
membranes69. This could be directly linked with the continued and efficient release from lipid 
carriers in PBS medium in contrast to the low and ceased release in pure water medium (Figure 
7, Table 4).  
The release (%) measured after 24 hrs for bulk cubic phase and cubosomes in both medium, 
i.e. water and PBS always decreased with the increase in drug: lipid ratio (Table 4). This again 
confirms that the release rate depends on the drug concentration, thus following the first-order 
release kinetics.          
 
Conclusions and perspectives 
In this work we have compared the release properties of two different lipid nanocarrier 
systems. Bulk lipid cubic phase and cubosomes were studied under similar conditions 
of drug to lipid ratios and the volumes of release media. The release in both lipid systems 
followed a mechanism described by Korsmeyer-Peppas equation revealing the Fickian 
diffusion through the porous matrix57-58. However, the diffusion from cubosomes in PBS 
medium was anomalous, involving either or a combination of non-Fickian diffusion and 
erosion57-58. The latter may correspond to the interaction of PBS buffer molecules with 
lipid bilayer structures68-69 that are enclosed by small cubosome particles. This can be 
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verified from the efficient and rapid release in PBS medium compared to the almost 
ceased release in water medium (Figure 7).  
The release from bulk lipid systems was sustained with respect to the dispersed colloidal 
cubosomes due to apparent reasons. Although both lipid systems exhibit self-assembled 
cubic nanostructures with highly tortuous porous networks, the effective length scales 
experienced by drug molecules differ enormously. Cubosomes particles are small in size 
with rather high interfacial area leading to the burst release while longer length scales of 
bulk cubic phase enable prolonged drug release. Moreover, the wider and more number 
of aqueous channels of Im3m cubic phase contribute in the enhanced release from 
cubosomes. At this stage we cannot comment on the role of overall high viscosity of 
bulk cubic phases in the release kinetics and leave it for further in-depth studies. This 
study shades light on important aspect of comparing two emerging drug delivery systems 
based on the nanoscale self-assembly of lipid molecules in aqueous medium. The results 
obtained are potentially useful for predictable design and optimization of these 
nanocarrier systems. 
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